Rodent research suggests feasibility of restoring neuron function
Research from the School of Medicine at The University of Texas Health Science Center at San Antonio suggests the exciting possibility of using cell transplants to treat schizophrenia.
Cells called “interneurons” inhibit activity within brain regions, but this braking or governing function is impaired in schizophrenia. Consequently, a group of nerve cells called the dopamine system go into overdrive. Different branches of the dopamine system are involved in cognition, movement and emotions.
“Since these cells are not functioning properly, our idea is to replace them,” said study senior author Daniel Lodge, Ph.D., assistant professor of pharmacology in the School of Medicine.
Transplant restored normal function
Dr. Lodge and lead author Stephanie Perez, graduate student in his laboratory, biopsied tissue from rat fetuses, isolated cells from the tissue and injected the cells into a brain center called the hippocampus. This center regulates the dopamine system and plays a role in learning, memory and executive functions such as decision making. Rats treated with the transplanted cells have restored hippocampal and dopamine function.
Stem cells are able to become different types of cells, and in this case interneurons were selected. “We put in a lot of cells and not all survived, but a significant portion did and restored hippocampal and dopamine function back to normal,” Dr. Lodge said.
‘You can essentially fix the problem’
Unlike traditional approaches to treating schizophrenia, such as medications and deep-brain stimulation, transplantation of interneurons potentially can produce a permanent solution. “You can essentially fix the problem,” Dr. Lodge said. “Ultimately, if this is translated to humans, we want to reprogram a patient’s own cells and use them.”
The Latest on: Schizophrenia
- Concert Pharma launches mid-stage study of CTP-692 in schizophreniaon December 2, 2019 at 1:13 pm
Concert Pharmaceuticals (CNCE-3.4%) initiates a Phase 2 clinical trial evaluating CTP-692 for the adjunctive treatment of schizophrenia. The primary endpoint is the change from baseline in a ...
- Concert Pharmaceuticals Initiates CTP-692 Phase 2 Trial in Schizophreniaon December 2, 2019 at 4:50 am
LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2 clinical trial evaluating CTP-692 as an adjunctive treatment for ...
- Mitochondrial Dysfunction and Changes in High-Energy Compounds in Different Cellular Models Associated to Hypoxia: Implication to Schizophreniaon December 2, 2019 at 2:17 am
Schizophrenia (SZ) is a multifactorial mental disorder, which has been associated with a number of environmental factors, such as hypoxia. Considering that numerous neural mechanisms depends on ...
- ‘I didn’t know if he was alive’: Mother of man with schizophrenia slammed by CPD officer speaks outon December 1, 2019 at 7:36 pm
Keshia Johnson said she was on the phone with her son, Bernard Kersh, when officers approached the 29-year-old. Kersh, who is diagnosed with schizophrenia, was slammed by a Chicago police officer ...
- Missing man suffering from schizophrenia last seen leaving Ypsilanti group homeon December 1, 2019 at 7:09 am
Mr. Summerhill is currently listed as an endangered missing person and has been without his medication for schizophrenia and is not dressed for the cold weather, police say. He was last seen wearing a ...
- I Am Afraid of Developing Schizophrenia, Although I Am 29, I Have A Lot of Risk Factorson November 30, 2019 at 2:20 pm
Two days ago, I started having an obsession about the possibility of getting schizophrenia. I am now 29 years old, and I know that this lowers the probability of getting schizophrenia. However, I ...
- Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteineon November 28, 2019 at 4:45 am
Human postmortem studies suggest a major role for abnormalities in GABAergic interneurons in the prefrontal cortex in schizophrenia. Cortical interneurons differentiated from induced pluripotent stem ...
- Understanding the Phases of Schizophreniaon November 26, 2019 at 12:41 pm
Schizophrenia is a chronic mental illness. It affects about 1 percent of the population, although the condition’s exact prevalence is hard to obtain. Each phase of schizophrenia has symptoms that help ...
- Acadia's Schizophrenia Trial Is A Clear Positive For The Stockon November 26, 2019 at 7:59 am
The 34 mg dose should a strong efficacy. The technical chart shows the stock is near a breakout. Acadia Pharmaceuticals (ACAD) reported positive top line results for its ADVANCE study of negative ...
- Acadia's Nuplazid rebounds in schizophrenia with study winon November 26, 2019 at 7:23 am
Acadia's Nuplazid suffered a big loss in July after a late-stage trial as an add-on treatment for schizophrenia fell flat. But that study wasn't Nuplazid's last go at the indication, and now a phase 2 ...
via Google News and Bing News
